Robins Global News & Noticias

COVID-19 Map Tracker | COVID-19 News Features

  • Career Exam Study
    Career Exam Study
  • Digital Products
    Digital Products
  • Teen Drug Prevention
    Teen Drug Prevention
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News

RobinsPost News Network

+ Larger Font | - Smaller Font

feed-image RSS

Press Releases

Trusted reliable news sources from around the web. We offer special news reports, topic news videos, and related content stories. Truly a birds eye view on news.

Press Release: SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of FITB and BIDU of Upcoming Deadlines

WILMINGTON, Del., May 26, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the following companies:

Fifth Third Bancorp (NASDAQ GS: FITB)

Class Period: February 26, 2016 – March 6, 2020
Lead Plaintiff Deadline: June 8, 2020

According to the Complaint, on March 2, 2020, Fifth Third filed an Annual Report on Form 10-K with the SEC, reporting the Company’s financial and operating results for the quarter and year ended December 31, 2019 (the “2019 10-K”).  According to the 2019 10-K, U.S. Consumer Financial Protection Bureau (“CFPB”) staff “notified Fifth Third that it intends to file an enforcement action in relation to alleged unauthorized account openings.”

However, the true scope of the Company’s alleged wrongdoing, and potential liability with respect to unauthorized account openings, was left undisclosed in the 2019 10-K, and was actively downplayed by the Company, thereby causing the Company’s stock price to continue to trade at artificially inflated prices throughout the remainder of the Class Period.

Then, on March 9, 2020, the CFPB announced that it had filed a lawsuit against Fifth Third Bank in federal court, disclosing significant additional information concerning its investigation into the Company that the Company had previously failed to disclose.  Specifically, the CFPB “allege[d] that for several years,” and until at least 2016, “Fifth Third [Bank], without consumers’ knowledge or consent: opened deposit and credit-card accounts in consumers’ names; transferred funds from consumers’ existing accounts to new, improperly opened accounts; enrolled consumers in unauthorized online-banking services; and activated unauthorized lines of credit on consumers’ accounts.”  The CFPB further alleged that, “despite knowing since at least 2008 that employees were opening unauthorized consumer-financial accounts, Fifth Third [Bank] took insufficient steps to detect and stop the conduct and to identify and remediate harmed consumers.”  Consequently, the CFPB concluded that Fifth Third Bank “violated the Consumer Financial Protection Act’s prohibition against unfair and abusive acts or practices as well as the Truth in Lending Act and the Truth in Savings Act and their implementing regulations.”

To learn more, visit:

Baidu, Inc. (NASDAQ GS: BIDU)

Class Period: March 16, 2019 – April 7, 2020
Lead Plaintiff Deadline: June 22, 2020

According to the Complaint, on April 7, 2020, post-market, China's internet regulator, the Cyberspace Administration of China ("CAC"), ordered Baidu to clean up improper information and halt the spread of "low-brow content."  Specifically, the CAC stated that search engine Baidu's content review on some of its news feed channels is not "strict," "exerted bad influence to the society," and violated relevant Chinese laws and regulations.

To learn more, visit:

If you would like to discuss any of these lawsuits and your rights cost and obligation free, please contact Seth D. Rigrodsky or Timothy J. MacFall toll-free at (888) 969-4242 or  by e-mail at This email address is being protected from spambots. You need JavaScript enabled to view it..

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.                                      
Seth D. Rigrodsky
Timothy J. MacFall
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more ...

Press Release: Zomedica Pharmaceuticals Corp. Announces $20 Million Public Offering

ANN ARBOR, Mich., May 26, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of a public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant. Each common share (or common share equivalent) is being sold in the offering together with one two-year warrant to purchase one common share at an exercise price of $0.15 per common share. There is no established public trading market for the warrants, and Zomedica does not expect a market to develop.

H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

The gross proceeds from this offering are expected to be approximately $20.0 million, before deducting placement agent’s fees and other estimated offering expenses payable by the Company, assuming none of the warrants sold in this offering are exercised for cash. The offering is expected to close on or about May 29, 2020, subject to the satisfaction of customary closing conditions.

Zomedica intends to use the net proceeds from this offering for the continued development of its TRUFORMA™ diagnostic platform, including making milestone payments, as they come due, under its existing license and collaboration agreements, and other general corporate and working capital purposes.

The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-238322) previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on May 26, 2020. A preliminary prospectus relating to the securities being offered was filed with the SEC on May 22, 2020 and is available on the SEC’s website at Electronic copies of the final prospectus relating to the offering may be obtained, when available, from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or by emailing This email address is being protected from spambots. You need JavaScript enabled to view it. or at the SEC’s website at

The common shares (or common share equivalents) and the warrants are not being offered to residents of Canada or persons in Canada. The common shares (or common share equivalents), warrants and the common shares underlying the warrants are being sold on the basis of prospectus exemptions under applicable Canadian securities laws on the basis that the securities will not be distributed back into Canada.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary diagnostic company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit

Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”)  within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to Zomedica’s expectations regarding the public offering. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: market conditions, the completion of the public offering, the risk that the public offering will not be consummated, the satisfaction of customary closing conditions related to the public offering and the intended use of net proceeds from the public offering, as well as uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and pilot and pivotal studies, uncertainty as to the likelihood and timing of regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection, risks related to the novel coronavirus disease 2019 (“COVID-19”) and its impact upon Zomedica’s business operations generally, including  Zomedica’s ability to develop its diagnostic and therapeutic products,  and the other risk factors disclosed in our filings with the Securities and Exchange Commission and under our profile on SEDAR at Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contacts
Shameze Rampertab, CPA, CA, Interim CEO and CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 647.283.3630

PCG Advisory Group
Kirin Smith, COO
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 646.863.6519

Media Contact
Meredith Newman
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 734.369.2555

Read more ...

Press Release: Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company, today announced that it has priced an underwritten public offering of 555,556 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (“Series A Preferred Stock”) at a price of $18.00 per share, with expected gross proceeds to Fortress of approximately $10 million. In addition, Fortress has granted the underwriters a 45-day option to purchase up to 83,333 additional shares of its Series A Preferred Stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about May 29, 2020, subject to customary closing conditions.

The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, Inc. are acting as joint bookrunning managers for the offering.

Fortress intends to use the net proceeds from the public offering for its operations, including, but not limited to, general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product, and working capital.

This offering is being made only by means of a written prospectus and related prospectus supplement that form a part of the registration statement. A copy of the final prospectus supplement and accompanying prospectus related to this offering may be obtained from any of the underwriters, including the offices of The Benchmark Company, LLC, Attn: Prospectus Department, 150 E 58th Street, 17th floor, New York, NY 10155, 212-312-6700, Email: This email address is being protected from spambots. You need JavaScript enabled to view it., and the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it..  You may also obtain these documents for free when they are available by visiting the Securities Exchange Commission’s (“SEC”) website at

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was recently ranked number 10 in Deloitte’s 2019 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentage of fiscal year revenue growth over a three-year period.  Fortress is focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value while mitigating risk for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited), St. Jude Children’s Research Hospital and Nationwide Children’s Hospital. 

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees’ and consultants’ ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all;  our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Company Contacts:
Jaclyn Jaffe and William Begien
Fortress Biotech, Inc.
(781) 652-4500
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
This email address is being protected from spambots. You need JavaScript enabled to view it. 


Read more ...

Press Release: ForgeRock supports Telkomsel to secure its customer identities and power digital ecosystem ambitions

JAKARTA, Indonesia, May 27, 2020 (GLOBE NEWSWIRE) -- ForgeRock®, the leading provider in digital identity, has been awarded a contract to deploy the ForgeRock Identity Platform™ for Telkomsel, in a major push by the leading mobile network operator to improve its digital readiness. The deal will see ForgeRock deliver an automated identity lifecycle to support Telkomsel’s consumer base across web, mobile, and multiple applications.

Recognising that its customers were quickly moving towards digital services and demanding more seamless experiences, Telkomsel sought an identity management system that would underpin its digital transformation ambitions and modernise its MyTelkomsel app. The solution had to scale to 200 million identities, process seven thousand transactions per second, and handle the lifecycle of customer identities across multiple markets.

ForgeRock was chosen due to its flexibility to work in hybrid environments. The plan for Telkomsel is to migrate entirely to a cloud-based infrastructure. The ForgeRock platform provides consumer identity and access management and orchestration for key online channels and manages millions of identities for Telkomsel which resulted in dramatic improvements in deployment efficiency.

Telkomsel CIO Pak Bharat Alva, said: “Our partnership with ForgeRock is one of the building blocks to digital transformation initiatives for Telkomsel. The large scale and quick time to market requirements being one of the main reasons for Telkomsel to partner with ForgeRock.”

Telkomsel’s implementation of ForgeRock to centralise identity management across its network is powering Telkomsel’s creation of a new digital ecosystem of mobile, web and third-party applications, providing customers with a rich and seamless experience. The solution now enables customers to conveniently use the same identity across applications and devices including the MyTelkomsel app and online portal and, by performing identity and access actions themselves, Telkomsel’s IT administrators are freed up for other projects.

“ForgeRock’s focus on customer success and involvement throughout the project duration is highly appreciated by Telkomsel and is one of the key reasons for successful implementation of the CIAM platform,” said Pak Rudy Jayadi, Telkomsel VP IT Digital Enablement. This implementation will enable Telkomsel to deliver more innovations to delight our customers’ experience in digital services.

David Hope, SVP of APJ at ForgeRock, said: “Telkomsel's commitment to digital transformation is a true mark of its leadership position and has been the driving reason behind its growth. We're excited to further accelerate and future proof Telkomsel's digital footprint through rethinking identity management for their millions of customers. ForgeRock’s Identity Platform will enable Telkomsel to expand its mobile app ecosystem, adopt DevOps, and look to Cloud solutions, all while creating a pleasant experience for customers through self service capabilities.”

About ForgeRock

ForgeRock®, the leader in digital identity, delivers modern and comprehensive Identity and Access Management solutions for consumers, employees and things to simply and safely access the connected world. Using ForgeRock, more than a thousand global customer organizations orchestrate, manage, and secure the complete lifecycle of identities from dynamic access controls, governance, APIs, and storing authoritative data – consumable in any cloud or hybrid environment. The company is privately held, and headquartered in SanFrancisco, California, with offices around the world. For more information and free downloads, visit or follow ForgeRock on social media:

Facebook ForgeRock |Twitter @ForgeRock | LinkedIn ForgeRock |

Media Contact:

Dave De Jear
ForgeRock Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more ...

Press Release: Ultimate Guide for Collegiate Football Fanatics Released

KING OF PRUSSIA, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- After developing a love for college football after his older brother attended the University of Pittsburgh, author Gary Hudson compiled years of research to provide readers with a book that honors the legacy of universities across the country.  His recently released book, “The History of College Nicknames, Mascots and School Colors”, focuses on schools with Division 1A football programs. College alumni, staff and sports fans are going to enjoy learning about their favorite school’s historic background.

Researching over 120 schools in the US, Hudson spotlights colleges from Appalachian State University to Western Michigan University. For every school highlighted, there is a thoroughly researched account that educates readers about how that school’s persona came to be which includes their nicknames, mascots and school colors. A perfect light read filled with fascinating information, this charming guide is certainly full of heart.

“Reading through makes one feel like they are alumni or part of the institution,” says a reviewer from Pacific Book Review. “Gary Hudson is engaging and makes the reader get the impression of knowing so much about the various learning institutions written about in the book.”

“The History of College Nicknames, Mascots and School Colors” by Gary Hudson is an incredible look at major universities in the US. Fans of these colleges will be eager to search up their own school and learn all the unique details about how they came to be.


“The History of College Nicknames, Mascots and School Colors”

By Gary Hudson

ISBN: 9781796072556 (softcover); 9781796072563 (hardcover); 9781796072570 (electronic)

Available at the Xlibris Online Bookstore, Amazon and Barnes & Noble

About the author

Gary L. Hudson is an airport manager that has been working in the field of aviation for the past twenty-seven years. He graduated from Embry-Riddle Aeronautical University (Daytona Beach, Florida) with a BS degree in aeronautical studies and concentration in airport management. He is also a licensed pilot. In 1976, he started following college athletics, specifically football, when his older brother began his freshmen year at the University of Pittsburgh. From that time moving forward, he became very interested in wanting to know how colleges derived their respective nicknames, mascots, and school colors. He began writing “The History of College Nicknames, Mascots and School Colors” in 1995 and hopes that it helps readers grow closer to their favorite schools. To learn more, please visit


Xlibris Publishing, an Author Solutions, LLC imprint, is a self-publishing services provider created in 1997 by authors, for authors. By focusing on the needs of creative writers and artists and adopting the latest print-on-demand publishing technology and strategies, we provide expert publishing services with direct and personal access to quality publication in hardcover, trade paperback, custom leather-bound and full-color formats. To date, Xlibris has helped to publish more than 60,000 titles. For more information, visit or call 1-888-795-4274 to receive a free publishing guide.



Courtney Vasquez
This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more ...

Press Release: 新しい患者由来オルガノイドモデルを含め腫瘍学前臨床研究プラットフォームを拡張

本資料は、Crown Bioscience Inc.が 2020 年 5月 26日に発表したプレスリリースの和文抄訳であり、内容につきましては英語原文が優先されます。

サンディエゴ発, May 27, 2020 (GLOBE NEWSWIRE) -- Crown Bioscience(以下「CrownBio」)は本日、独自のオルガノイドプラットフォームを拡張し、130のHubrecht Organoid Technology(以下「HUB」)の患者由来オルガノイド(Patient-derived organoids、以下「PDO」)を追加したと発表した。これは、CrownBioの革新的なオルガノイドプラットフォームの開発、抗腫瘍薬の創薬サービスのためのHUB PDOの最初の大規模な商業的利用の重要なマイルストーンである。

オルガノイド技術は腫瘍学の医薬品開発に革命を起こし、伝統的なワークフローを変えている。 CrownBioはHUBから独占的なライセンスを取得しており、Clevers研究所によって開発された世界をリードするHUB Organoid Technologyを使用し、腫瘍薬の前臨床医薬品開発と検証サービスを提供している。

CrownBioの最高科学責任者であるHenry Liは以下のように述べている。「オルガノイドモデルは、腫瘍学研究の前臨床試験の実施方法に革命をもたらします。オルガノイドを使用することで、薬物スクリーニングは現在の線形ワークフローからマトリクス化されたハイスループットスクリーニングアプローチに進化し、リード化合物を簡単に測定可能かつ臨床的に関連するモデルシステムで複数の患者集団において同時に検証できるようになります。」

今回、新たに利用可能となったPDOモデルは、すでにCrownBioが確立し、拡大し続けている患者由来のオルガノイド(PDX-derived organoids 、以下「PDXO」))のプラットフォームに加わる。PDXOはHUBプロトコルを使用し、世界最大の市販PDXパネルであるCrownBioのPDXコレクションから作製されている。患者組織由来のPDOとPDX由のPDXOの補完的なパネルは、由来するPDXモデルとともに創薬研究方法を変える機会を提供する。

In vitroin vivoの患者由来モデルを組み合わせたコレクションは、臨床的に関連し予測性が高い。対応するモデルのペアは、in vitroからin vivoの研究へのより効率的でデータに基づく移行を可能とし、抗がん剤の成功率を高めるのに役立つ。

HUBのCEOであるRob Vries博士は以下のように述べている。「HUB オルガノイドバイオバンクが腫瘍学の創薬のために幅広い研究コミュニティーで利用できるようになることを嬉しく思います。CrownBioとのパートナーシップを通じて、製薬及びバイオテクノロジー企業に、抗がん剤開発プログラムの変革に必要な最先端のモデルを提供し続けています。」



CrownBioのオルガノイドプラットフォームは、世界中のクライアントが利用可能である。 新たに取得したPDOモデルは、CrownBioへの移管を完了しており、薬効性と薬効力の評価、併用治療の最適化及びリード化合物の選定のための研究に利用可能である。

About Crown Bioscience Inc.

JSRライフサイエンス株式会社の関連会社であるCrown Bioscience Inc.は、トランスレーショナルリサーチを通じて創薬研究開発を支援し、ソリューションを提供するグローバル企業である。CrownBioの疾患関連モデルと予測ツールの幅広いポートフォリオにより、オンコロジー、代謝疾患、炎症性疾患領域におけるより優れた開発候補化合物の選定が可能となる。詳しくは 次のサイトを閲覧されたい。

About HUB

Hubrecht Organoid Technology(以下「HUB」)は、Royal Netherlands Academy of Sciencesおよび University Medical Center Utrecht)によって設立された。創薬と開発、(前)臨床試験における患者層別化、予測診断、個別化医療及びコンパニオン診断薬のためのパラダイムシフトプラットフォームを構成している。

HUBは、成体幹細胞由来のヒト上皮組織から「ミニ臓器」(HUB オルガノイド) を作り出す方法を発見したHans Clevers教授の先駆的研究を活用している。Living biobankの一部であるHUBオルガノイドは、ゲノム配列、発現プロファイリング、既存および開発中の薬剤の感度が特徴的であり、遺伝子情報と薬剤応答性にリンクするデータベースを確立している。HUBは特許取得済みのオルガノイド技術をライセンス提供し、(前)臨床及び臨床試験サービス、研究開発コラボレーション、予測診断、及び「生きているバイオバンク」へのアクセスを提供します。詳細については、を閲覧されたい。


Crown Bioscience
Jody Barbeau
This email address is being protected from spambots. You need JavaScript enabled to view it.

Svenja Meiler
This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more ...

More Articles ...

Company Information

Official Content Providers


We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2020 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, Faroo News, and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.